1. Merck leaps into COVID vaccine race — Evofem Biosciences gets FDA approval for new non-hormonal contraceptive — Sanofi sells $13 billion stake in Regeneron — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Any info on d-path sales ?

Discussion in 'GI Path' started by Anonymous, Sep 16, 2010 at 11:47 AM.

  1. Anonymous

    Anonymous Guest

    Can anyone provide some honest feedback on d-path ? Realistic earnings for sales position ? Range for base salary ? Sales culture and management ? Thanks.
     
  2. Anonymous

    Anonymous Guest

    Run for the hills. This is a dead end job and market entry is almost impossiblel
     
  3. Anonymous

    Anonymous Guest

    gipp tells everyone they are a GI company and slams competitors who do anything else but GI. Now gipp does (tries anyway) to do derm, heme...etc. Derm market is spoken for...find another job.
     
  4. Anonymous

    Anonymous Guest

    how are the derm and heme doing? Are they buying up labs to get in the game or opening it under their roof?
     
  5. Anonymous

    Anonymous Guest

    All under their own roof. A lot of money spent. If it doesn't work, they'll just use TV as a scape goat. Too bad, TV is good people.